Literature DB >> 21833082

A continuum model for tumour suppression.

Alice H Berger1, Alfred G Knudson, Pier Paolo Pandolfi.   

Abstract

This year, 2011, marks the forty-year anniversary of the statistical analysis of retinoblastoma that provided the first evidence that tumorigenesis can be initiated by as few as two mutations. This work provided the foundation for the two-hit hypothesis that explained the role of recessive tumour suppressor genes (TSGs) in dominantly inherited cancer susceptibility syndromes. However, four decades later, it is now known that even partial inactivation of tumour suppressors can critically contribute to tumorigenesis. Here we analyse this evidence and propose a continuum model of TSG function to explain the full range of TSG mutations found in cancer.

Entities:  

Mesh:

Year:  2011        PMID: 21833082      PMCID: PMC3206311          DOI: 10.1038/nature10275

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  69 in total

1.  Cancer biology. A matter of dosage.

Authors:  Riccardo Fodde; Ron Smits
Journal:  Science       Date:  2002-10-25       Impact factor: 47.728

Review 2.  Tumor suppressor genetics.

Authors:  Shannon R Payne; Christopher J Kemp
Journal:  Carcinogenesis       Date:  2005-09-08       Impact factor: 4.944

3.  Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining.

Authors:  J D Rowley
Journal:  Nature       Date:  1973-06-01       Impact factor: 49.962

4.  A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language?

Authors:  Leonardo Salmena; Laura Poliseno; Yvonne Tay; Lev Kats; Pier Paolo Pandolfi
Journal:  Cell       Date:  2011-07-28       Impact factor: 41.582

5.  Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fate.

Authors:  Theresa A Proia; Patricia J Keller; Piyush B Gupta; Ina Klebba; Ainsley D Jones; Maja Sedic; Hannah Gilmore; Nadine Tung; Stephen P Naber; Stuart Schnitt; Eric S Lander; Charlotte Kuperwasser
Journal:  Cell Stem Cell       Date:  2011-02-04       Impact factor: 24.633

6.  Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells.

Authors:  Omer H Yilmaz; Riccardo Valdez; Brian K Theisen; Wei Guo; David O Ferguson; Hong Wu; Sean J Morrison
Journal:  Nature       Date:  2006-04-05       Impact factor: 49.962

7.  The telomerase inhibitor PinX1 is a major haploinsufficient tumor suppressor essential for chromosome stability in mice.

Authors:  Xiao Zhen Zhou; Pengyu Huang; Rong Shi; Tae Ho Lee; Gina Lu; Zhihong Zhang; Roderick Bronson; Kun Ping Lu
Journal:  J Clin Invest       Date:  2011-03-23       Impact factor: 14.808

Review 8.  Cancer genes and the pathways they control.

Authors:  Bert Vogelstein; Kenneth W Kinzler
Journal:  Nat Med       Date:  2004-08       Impact factor: 53.440

9.  Mutation and cancer: statistical study of retinoblastoma.

Authors:  A G Knudson
Journal:  Proc Natl Acad Sci U S A       Date:  1971-04       Impact factor: 11.205

10.  Pten dose dictates cancer progression in the prostate.

Authors:  Lloyd C Trotman; Masaru Niki; Zohar A Dotan; Jason A Koutcher; Antonio Di Cristofano; Andrew Xiao; Alan S Khoo; Pradip Roy-Burman; Norman M Greenberg; Terry Van Dyke; Carlos Cordon-Cardo; Pier Paolo Pandolfi
Journal:  PLoS Biol       Date:  2003-10-27       Impact factor: 8.029

View more
  207 in total

1.  The PTEN Tumor Suppressor Forms Homodimers in Solution.

Authors:  Frank Heinrich; Srinivas Chakravarthy; Hirsh Nanda; Antonella Papa; Pier Paolo Pandolfi; Alonzo H Ross; Rakesh K Harishchandra; Arne Gericke; Mathias Lösche
Journal:  Structure       Date:  2015-08-20       Impact factor: 5.006

2.  A PTEN inhibitor displays preclinical activity against hepatocarcinoma cells.

Authors:  Giuseppa Augello; Roberto Puleio; Maria Rita Emma; Antonella Cusimano; Guido R Loria; James A McCubrey; Giuseppe Montalto; Melchiorre Cervello
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

Review 3.  Epigenetics of lung cancer.

Authors:  Scott M Langevin; Robert A Kratzke; Karl T Kelsey
Journal:  Transl Res       Date:  2014-03-12       Impact factor: 7.012

4.  Menin immunoreactivity in secretory granules of human pancreatic islet cells.

Authors:  Larisa V Debelenko; Sunita Agarwal; Qiang Du; Wusheng Yan; Heidi S Erickson; Mones Abu-Asab; Mark A Raffeld; Steven K Libutti; Stephen J Marx; Michael R Emmert-Buck
Journal:  Appl Immunohistochem Mol Morphol       Date:  2014 Nov-Dec

5.  Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs.

Authors:  Yvonne Tay; Lev Kats; Leonardo Salmena; Dror Weiss; Shen Mynn Tan; Ugo Ala; Florian Karreth; Laura Poliseno; Paolo Provero; Ferdinando Di Cunto; Judy Lieberman; Isidore Rigoutsos; Pier Paolo Pandolfi
Journal:  Cell       Date:  2011-10-14       Impact factor: 41.582

6.  The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation.

Authors:  Su Jung Song; Keisuke Ito; Ugo Ala; Lev Kats; Kaitlyn Webster; Su Ming Sun; Mojca Jongen-Lavrencic; Katia Manova-Todorova; Julie Teruya-Feldstein; David E Avigan; Ruud Delwel; Pier Paolo Pandolfi
Journal:  Cell Stem Cell       Date:  2013-07-03       Impact factor: 24.633

7.  The High Mobility Group A proteins contribute to thyroid cell transformation by regulating miR-603 and miR-10b expression.

Authors:  Paula Mussnich; Daniela D'Angelo; Vincenza Leone; Carlo Maria Croce; Alfredo Fusco
Journal:  Mol Oncol       Date:  2013-01-17       Impact factor: 6.603

8.  Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas.

Authors:  Eleonora Sementino; Craig W Menges; Yuwaraj Kadariya; Suraj Peri; Jinfei Xu; Zemin Liu; Richard G Wilkes; Kathy Q Cai; Frank J Rauscher; Andres J Klein-Szanto; Joseph R Testa
Journal:  J Cell Physiol       Date:  2018-06-15       Impact factor: 6.384

Review 9.  Regulation and modulation of PTEN activity.

Authors:  Elahe Naderali; Amir Afshin Khaki; Jafar Soleymani Rad; Alireza Ali-Hemmati; Mohammad Rahmati; Hojjatollah Nozad Charoudeh
Journal:  Mol Biol Rep       Date:  2018-08-25       Impact factor: 2.316

Review 10.  How many molecular subtypes? Implications of the unique tumor principle in personalized medicine.

Authors:  Shuji Ogino; Charles S Fuchs; Edward Giovannucci
Journal:  Expert Rev Mol Diagn       Date:  2012-07       Impact factor: 5.225

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.